Get the Stockscreener App
61.00
0.41%
0.25
After Hours:
61.00
Catalent Inc stock is traded at $61.00, with a volume of 1.47M.
It is up +0.41% in the last 24 hours and up +3.23% over the past month.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
See More
Previous Close:
$60.75
Open:
$60.95
24h Volume:
1.47M
Relative Volume:
0.90
Market Cap:
$11.04B
Revenue:
$4.42B
Net Income/Loss:
$-413.00M
P/E Ratio:
-46.92
EPS:
-1.3
Net Cash Flow:
$99.00M
1W Performance:
+3.39%
1M Performance:
+3.23%
6M Performance:
+11.27%
1Y Performance:
+55.97%
1-Day Range:
$60.70
$61.05
1-Week Range:
$58.91
$61.50
52-Week Range:
$36.74
$61.50
Catalent Inc Stock (CTLT) Company Profile
Name
Catalent Inc
Sector
Phone
(732) 537-6200
Address
14 SCHOOLHOUSE ROAD, SOMERSET, NJ
Compare CTLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTLT
Catalent Inc
|
61.00 | 11.04B | 4.42B | -413.00M | 99.00M | -1.30 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Catalent Inc Stock (CTLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-16-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-05-23 | Upgrade | Argus | Hold → Buy |
| Jul-20-23 | Initiated | Wells Fargo | Equal Weight |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jun-14-23 | Downgrade | Jefferies | Buy → Hold |
| May-22-23 | Downgrade | JP Morgan | Overweight → Neutral |
| May-15-23 | Downgrade | Deutsche Bank | Buy → Hold |
| May-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-17-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Nov-07-22 | Downgrade | Argus | Buy → Hold |
| Nov-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-16-21 | Initiated | Barclays | Overweight |
| Dec-10-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jun-25-20 | Initiated | Argus | Buy |
| Apr-21-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Oct-17-19 | Resumed | Stephens | Overweight |
| Aug-28-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jun-21-19 | Upgrade | Jefferies | Hold → Buy |
| Apr-16-19 | Upgrade | UBS | Neutral → Buy |
| Nov-07-18 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-09-18 | Initiated | UBS | Neutral |
| Mar-28-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-21-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-06-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-17 | Initiated | Needham | Hold |
| Sep-08-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Dec-01-16 | Initiated | Goldman | Neutral |
| Oct-20-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-21-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-20-16 | Upgrade | BofA/Merrill | Neutral → Buy |
View All
Catalent Inc Stock (CTLT) Latest News
Catalent, Inc. (NYSE:CTLT) Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Pharmaceutical Contract Development and Manufacturing Market to Witness 6.9% CAGR by 2031 | SkyQuest Technology - Benzinga
Bank of Montreal Can Purchases 1,169,044 Shares of Catalent, Inc. (NYSE:CTLT) - MarketBeat
Dynamic Technology Lab Private Ltd Invests $1.13 Million in Catalent, Inc. (NYSE:CTLT) - MarketBeat
Catalent, Inc. (NYSE:CTLT) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Quantbot Technologies LP Makes New Investment in Catalent, Inc. (NYSE:CTLT) - MarketBeat
CTLT (Catalent) Cash From Other Investing Activities : $0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Source: Novo Holdings expected to get EU approval for CatalentReuters - Marketscreener.com
Catalent (NYSE:CTLT) Hits New 52-Week HighHere's What Happened - MarketBeat
Novo Holdings' $16.5 Billion Acquisition of Catalent Faces EU De - GuruFocus.com
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 266,690 Shares of Catalent, Inc. (NYSE:CTLT) - MarketBeat
Catalent stock soars to 52-week high, hits $61.32 By Investing.com - Investing.com Nigeria
Novo Holdings set to win EU nod for $16.5 bln Catalent deal, source says - Reuters
EU antitrust regulators set to okay $16.5 billion Novo Holdings, Catalent deal, source says - Marketscreener.com
Novo Holdings set to win EU nod for $16.5 billion Catalent deal, source says - Yahoo Finance UK
Catalent gains on reports it's likely to be granted EU approval for Novo Holdings deal (update) - Seeking Alpha
Catalent stock soars to 52-week high, hits $61.32 - Investing.com
Catalent (NYSE:CTLT) Rating Lowered to "Sell" at StockNews.com - MarketBeat
Catalent Stock: Analyst Estimates & Ratings - Nasdaq
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up - MSN
EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6 - MSN
Catalent, Inc. (NYSE:CTLT) Holdings Raised by Alpine Associates Management Inc. - MarketBeat
EU regulators see info from rivals, customers in Catalent's sale to Novo Holdings - MSN
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal - MSN
Softgel Capsule Market Future Business Opportunities - openPR
Narrow-Moat Catalent's Acquisition by Novo Nordisk Remains on Track; Boosting Wegovy Manufacturing - Morningstar
Quest Partners LLC Buys 36,652 Shares of Catalent, Inc. (NYSE:CTLT) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Increases Stock Holdings in Catalent, Inc. (NYSE:CTLT) - MarketBeat
500,000 Shares in Catalent, Inc. (NYSE:CTLT) Purchased by Mizuho Markets Americas LLC - MarketBeat
GMP Cell Banking Market Hits New High | Major Giants Catalent, BioIVT, Abzena - openPR
Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings - MSN
Curi RMB Capital LLC Trims Stake in Catalent, Inc. (NYSE:CTLT) - MarketBeat
Nomura Holdings Inc's Strategic Reduction in Catalent Inc Shares - GuruFocus.com
Catalent director Ryan Michelle R sells $167,160 in stock By Investing.com - Investing.com Nigeria
Catalent director Ryan Michelle R sells $167,160 in stock - Investing.com
ING Groep NV Acquires 699,851 Shares of Catalent, Inc. (NYSE:CTLT) - MarketBeat
Janus Henderson Group PLC's Strategic Reduction in Catalent Inc Holdings - GuruFocus.com
High Potency API Contract Manufacturing Market Forecast, 2025-2030 - GlobeNewswire Inc.
Catalent (NYSE:CTLT) Stock Rating Upgraded by StockNews.com - MarketBeat
Capital World Investors Expands Stake in Catalent Inc - GuruFocus.com
EU regulators seek info from rivals, customers in Catalent sale to Novo HoldingsReuters - Seeking Alpha
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal - Reuters
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up - MSN
Novo-Catalent Deal Represents ‘Defining Moment’ for CDMO Sector - BioSpace
Catalent's SWOT analysis: stock outlook amid acquisition talks, regulatory shifts - Investing.com Nigeria
Catalent, Inc. (NYSE:CTLT) Shares Acquired by Van ECK Associates Corp - MarketBeat
Olympiad Research LP Boosts Holdings in Catalent, Inc. (NYSE:CTLT) - MarketBeat
Catalent Inc Reports Q1 Fiscal 2025 Earnings: $1.02 Billion Reve - GuruFocus.com
Brokerages Set Catalent, Inc. (NYSE:CTLT) Price Target at $59.83 - MarketBeat
Novo Holdings Acquires Catalent Despite Financial Setback - Finimize
Catalent reports Q1 loss, misses market expectations - MSN
Catalent Inc Stock (CTLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):